Buy-back Announced
AnaptysBio outstanding common stock share buy-back
US$100m consideration
Announced 27 Mar 2026
Advisers
AnaptysBio outstanding common stock
Target
Not disclosed
- Target
- AnaptysBio outstanding common stock
- Acquirer
- AnaptysBio
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Pharma
Similar deals
- Aurinia Pharmaceuticals acquisition of Kezar Life Sciences Mar 2026 · US$51.5m · Biotech
- TELI Pharmaceuticals and Telomir Pharmaceuticals merger US$47.1m · Biotech
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech